Friday, October 4, 2024
Home Diseases conditions and syndromes FDA approves Miplyffa for treatment of Niemann-Pick disease, type C

FDA approves Miplyffa for treatment of Niemann-Pick disease, type C

by Medical Xpress
0 comment



The U.S. Food and Drug Administration has approved Zevra Therapeutics’ Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).

Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat associated with NPC in adults and children aged 2 years and older. The approval received priority review, orphan drug, rare pediatric disease, , and breakthrough therapy designations.

The approval is based on results from a randomized, double-blind, placebo-controlled 12-month trial in patients (ages 2 to 19 years) with a molecularly confirmed diagnosis of NPC.

The analysis included 50 patients randomly assigned (2:1) to treatment with weight-adjusted Miplyffa (31 to 124 mg) or placebo orally three times per day. Miplyffa resulted in slower disease progression as measured by the rescored four-domain NPC Clinical Severity Scale score. The most common side effects of Miplyffa treatment included upper respiratory tract infection, diarrhea, and decreased weight.

“The first-ever approval of a safe and effective drug option for NPC will undoubtedly support the essential medical needs of those suffering,” Janet Maynard, M.D., director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA Center for Drug Evaluation and Research, said in a statement.

More information:
More Information

Copyright © 2024 HealthDay. All rights reserved.

Citation:
FDA approves Miplyffa for treatment of Niemann-Pick disease, type C (2024, October 1)
retrieved 1 October 2024
from https://medicalxpress.com/news/2024-10-fda-miplyffa-treatment-niemann-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

You may also like

Leave a Comment

Edtior's Picks

Latest Articles

All Rights reserved, site designed by Yellohost.co.za